MDGN: Medgenics Twitter - Seeking Alpha

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 9, 9:57 AM Medgenics (MDGN): Q1 EPS of -$0.29 misses by $0.02. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, April 22, 10:15 AM Medgenics (MDGN +3.2%) expands the range of patent coverage for its therapeutic proteins and thereby broadens the scope of its intellectual property as the company receives a notice of allowance from the U.S. Patent Office. MDGN now has 45 patents granted. 1 Comment
Friday, February 8, 11:40 AM Medgenics (MDGN -7.3%) slips after pricing its offering of company stock and warrants at $5.25, near current levels. The company says it's bundling the shares and warrants together, with each unit sold at $5.25 consisting of one share of common stock and a warrant to purchase one-half of a share at an initial exercise price of $6.78. The medical technology and therapeutics company said it plans to sell 5.6M shares of stock in order to raise around $29.4M. Maxim Group is acting as sole book-running manager. 1 Comment [Healthcare, On the Move]
Thursday, December 6, 2012, 1:36 PM Medgenics (MDGN -1.2%) says it's received a Notice of Allowance from the Japanese Patent and Trademark Office for key claims protecting the use of it's Infradure Biopump technology. The technology provides interferon therapy for the treatment of hepatitis B, C, and D. MDGN has already been granted patents covering core Biopump technology in the U.S. and in the EU. Comment! [Healthcare, On the Move]
Wednesday, November 21, 2012, 1:18 PM Medgenics (MDGN +13.2%) gets a pop today after being granted a patent by the USPTO protecting the use of the company's Epodure Biopump technology for the treatment of anemia. The patent agency also allowed claims covering a similar method for delivery underlying it's Hemodure Biopump technology for sustained prophylactic treatment of hemophilia. MDGN's global portfolio now includes 36 patents issued, with 81 more pending. Comment! [Healthcare, On the Move]
Thursday, August 30, 2012, 9:52 AM Analyst Sharon di Stefano calls two upcoming trials of Medgenics' (MDGN -3%) Infraddure Biopump for treating hepatitis C as "a leap forward for viral medicine no less important than the first studies in HIV decades ago." And with the recent failure of a Bristol-Myers treatment in clinical trials, the timing is good. Still, with a number of rival drugs being trialled, one wonders whether di Stefano is guilty of hyperbole. 3 Comments [Healthcare]
Wednesday, June 20, 2012, 3:08 PM Shares of Medgenics (MDGN +25%) soar after the company says its Infradure Biopump has received an Orphan Drug Designation from the FDA to treat hepatitis D. The designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process. Seeking Alpha contributor Ray Dirks says the designation makes it a prime takeout target. Comment! [Healthcare, On the Move]

MDGN Medgenics

MDGN

Medgenics